Compare Huntington Bancshares Incorporated (HBAN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Sanofi SA — how do they compare? Huntington Bancshares Incorporated trades at $15.32 (market cap $31.04B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.1× Huntington Bancshares Incorporated's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Sanofi SA for 94 Days on average.
| HBAN | SNY | |
|---|---|---|
Market Cap | $31.04B | $95.18B |
Volume | 23,864,172 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $19.27 | $52.34 |
52-Week Low | $15.02 | $39.51 |
Typical Hold Time | 52 Days | 94 Days |
Enterprise Value | $49.57B | $114.48B |
Dividend Yield | 4.04% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.32, up 0.99% on the day, with a bearish technical signal and mixed earnings history. The company reported 2025 revenue of $8.13B and net income of $2.21B, with a P/E of 11.82 and ROE of 9.23%. Recent news highlights an increased prime rate to 7.00% and a revised 2027 earnings outlook due to margin pressures.
Outlook is cautious; analyst consensus is a Buy with a $19.60 price target, but near-term headwinds from higher interest rates and deposit costs pose risks. The stock offers value based on valuation metrics, yet investors should weigh margin pressures against shareholder return initiatives like the $550M buyback plan for 2026.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
